Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 19/20 | 0.72 |
| ▸ | IMPDH1 | P20839 | 14/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152776 | 1.00 | IMPDH2 (0.72) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1473162 | 0.94 | IMPDH2 (0.63) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1473007 | 0.93 | IMPDH2 (0.62) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1151979 | 0.93 | IMPDH2 (0.69) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1152865 | 0.93 | IMPDH2 (0.71) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1152863 | 0.93 | IMPDH2 (0.71) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1473096 | 0.92 | IMPDH2 (0.61) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1152735 | 0.91 | IMPDH2 (0.72) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1475906 | 0.90 | IMPDH2 (0.59) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL1473884 | 0.90 | IMPDH2 (0.58) | IMPDH2IMPDH1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| EP-0745074-B1 | 4-AMINO DERIVATIVES OF MYCOPHENOLIC ACID WITH IMMUNOSUPPRESSANT ACTIVITY | SYNTEX LLC (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-1995022535-A1 | 4-AMINO DERIVATIVES OF MYCOPHENOLIC ACID WITH IMMUNOSUPPRESSANT ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5441953-A | Immunosuppressants | SYNTEX (U.S.A.) INC. (US) | 1995-08-15 | — | — | US | disclosed |
| US-5380879-A | Immunosuppressants | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | IMPDH2 2041/4885IMPDH1 1995/4885HDAC3 1957/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | IMPDH2 2041/4885IMPDH1 1995/4885HDAC3 1957/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885IMPDH1 1/4885HDAC3 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.